Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer

详细信息    查看全文

• 作者：Rekha A. Kumbla ; Robert A. Figlin ; Edwin M. Posadas
• 刊名：Drugs
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：77
• 期：1
• 页码：17-28
• 全文大小：
• 刊物主题：Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1950
• 卷排序：77

文摘

Renal cell carcinoma (RCC) historically has had limited treatment options in the metastatic setting but in the last decade, a significant arsenal of new therapies has emerged. Specifically, targeted anti-angiogenic therapies through vascular endothelial growth factor (VEGF) inhibition and immunotherapy through PD-1 inhibition have become the foundation of metastatic RCC treatment increasing not only progression-free survival but also an improved overall survival with improved toxicity profiles compared with older therapies such as IL-2 and interferon. With the development of these newer medications, the optimal sequence and pairing of treatments is not yet well understood but important studies are ongoing as this information will allow for more effective and safe treatment of patients.